Novartis Completes Acquisition Of Avidity Biosciences

Reuters

Feb 27

Feb 27 (Reuters) - NOVARTIS ::
*NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY
*NOVARTIS - UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH LAUNCHES BEFORE 2030
*NOVARTIS - STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK
*NOVARTIS - HOLDERS OF AVIDITY COMMON STOCK BECAME ENTITLED TO RECEIVE USD 72.00 PER SHARE IN CASH

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 27-FEB-202614:00:00.06 GMT

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614851704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614851704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614851704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614851704","market":"us","top_or_hot":-1,"title":"Novartis Completes Acquisition Of Avidity Biosciences","media":"Reuters","content":"<html><body>Feb 27 (Reuters) - NOVARTIS <novn.s>::<br/>*NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY<br/>*NOVARTIS - UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH LAUNCHES BEFORE 2030<br/>*NOVARTIS - STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK<br/>*NOVARTIS - HOLDERS OF AVIDITY COMMON STOCK BECAME ENTITLED TO RECEIVE USD 72.00 PER SHARE IN CASH<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 27-FEB-202614:00:00.06 GMT</novn.s></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Completes Acquisition Of Avidity Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Completes Acquisition Of Avidity Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Feb 27 (Reuters) - NOVARTIS <novn.s>::<br/>*NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY<br/>*NOVARTIS - UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH LAUNCHES BEFORE 2030<br/>*NOVARTIS - STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK<br/>*NOVARTIS - HOLDERS OF AVIDITY COMMON STOCK BECAME ENTITLED TO RECEIVE USD 72.00 PER SHARE IN CASH<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 27-FEB-202614:00:00.06 GMT</novn.s></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nRSD9RSRrH:1","article_id":"2614851704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614851704","pubTimestamp":1772201741,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Feb 27 (Reuters) - NOVARTIS ::*NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY*NOVARTIS - UNLOCKS MULTI-B","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","RNA":"Atrium Therapeutics","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"诺华完成对Avidity Biosciences的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Feb 27 (Reuters) - NOVARTIS ::*NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY*NOVARTIS - UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH LAUNCHES BEFORE 2030*NOVARTIS - STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK*NOVARTIS - HOLDERS OF AVIDITY COMMON STOCK BECAME ENTITLED TO RECEIVE USD 72.00 PER SHARE IN CASH  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-FEB-202614:00:00.06 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}